Literature DB >> 9121429

The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme.

T P Cujec1, H Cho, E Maldonado, J Meyer, D Reinberg, B M Peterlin.   

Abstract

The human immunodeficiency virus (HIV) encodes a transcriptional transactivator (Tat), which binds to an RNA hairpin called the transactivation response element (TAR) that is located downstream of the site of initiation of viral transcription. Tat stimulates the production of full-length viral transcripts by RNA polymerase II (pol II). In this study, we demonstrate that Tat coimmunoprecipitates with the pol II holoenzyme in cells and that it binds to the purified holoenzyme in vitro. Furthermore, Tat affinity chromatography purifies a holoenzyme from HeLa nuclear extracts which, upon addition of TBP and TFIIB, supports Tat transactivation in vitro, indicating that it contains all the cellular proteins required for the function of Tat. By demonstrating that Tat interacts with the holoenzyme in the absence of TAR, our data suggest a single-step assembly of Tat and the transcription complex on the long terminal repeat of HIV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121429      PMCID: PMC232028          DOI: 10.1128/MCB.17.4.1817

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  HIV-1 Tat acts as a processivity factor in vitro in conjunction with cellular elongation factors.

Authors:  H Kato; H Sumimoto; P Pognonec; C H Chen; C A Rosen; R G Roeder
Journal:  Genes Dev       Date:  1992-04       Impact factor: 11.361

2.  Factors involved in specific transcription by mammalian RNA polymerase II. Identification and characterization of factor IIH.

Authors:  O Flores; H Lu; D Reinberg
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

3.  Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II.

Authors:  H Okamoto; C T Sheline; J L Corden; K A Jones; B M Peterlin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.

Authors:  S J Madore; B R Cullen
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 5.  Does HIV-1 Tat induce a change in viral initiation rights?

Authors:  B R Cullen
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

Review 6.  Transcriptional antitermination.

Authors:  J Greenblatt; J R Nodwell; S W Mason
Journal:  Nature       Date:  1993-07-29       Impact factor: 49.962

7.  TAR loop-dependent human immunodeficiency virus trans activation requires factors encoded on human chromosome 12.

Authors:  C E Hart; J C Galphin; M A Westhafer; G Schochetman
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.

Authors:  A Alonso; D Derse; B M Peterlin
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.

Authors:  K T Jeang; R Chun; N H Lin; A Gatignol; C G Glabe; H Fan
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat.

Authors:  X Lu; T M Welsh; B M Peterlin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more
  47 in total

1.  hnRNP U inhibits carboxy-terminal domain phosphorylation by TFIIH and represses RNA polymerase II elongation.

Authors:  M K Kim; V M Nikodem
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Transcriptional activation by artificial recruitment in mammalian cells.

Authors:  J Nevado; L Gaudreau; M Adam; M Ptashne
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

3.  Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain.

Authors:  Alexander Dorr; Veronique Kiermer; Angelika Pedal; Hans-Richard Rackwitz; Peter Henklein; Ulrich Schubert; Ming-Ming Zhou; Eric Verdin; Melanie Ott
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

4.  Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Authors:  Natallia Dziuba; Monique R Ferguson; William A O'Brien; Anthony Sanchez; Andrew J Prussia; Natalie J McDonald; Brian M Friedrich; Guangyu Li; Michael W Shaw; Jinsong Sheng; Thomas W Hodge; Donald H Rubin; James L Murray
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

5.  Kick-sTARting HIV-1 transcription elongation by 7SK snRNP deporTATion.

Authors:  Matjaz Barboric; Tina Lenasi
Journal:  Nat Struct Mol Biol       Date:  2010-08       Impact factor: 15.369

Review 6.  Regulation of HIV-1 transcription.

Authors:  K A Roebuck; M Saifuddin
Journal:  Gene Expr       Date:  1999

7.  Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex.

Authors:  N J Keen; M J Churcher; J Karn
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

8.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

9.  Targeting tat inhibitors in the assembly of human immunodeficiency virus type 1 transcription complexes.

Authors:  Iván D'Orso; Jocelyn R Grunwell; Robert L Nakamura; Chandreyee Das; Alan D Frankel
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription.

Authors:  C Ulich; A Dunne; E Parry; C W Hooker; R B Gaynor; D Harrich
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.